Literature DB >> 11481405

Functional fragments of ingested lactoferrin are resistant to proteolytic degradation in the gastrointestinal tract of adult rats.

H Kuwata1, K Yamauchi, S Teraguchi, Y Ushida, Y Shimokawa, T Toida, H Hayasawa.   

Abstract

Pharmaceutical and food-related applications of lactoferrin, an 80-kDa iron-binding glycoprotein found predominantly in milk, have attracted interest lately, but the process of digestion of lactoferrin has been poorly characterized. The digestive fate of bovine lactoferrin in adult rats after oral administration of a single dose and after dietary supplementation was studied by (125)I-labeling and by surface-enhanced laser desorption/ionization (SELDI) affinity mass spectrometry. The latter method was designed to detect multiple forms of degraded lactoferrin as simple molecular ion peaks corresponding to one of the core regions of lactoferrin, namely, the lactoferricin region (Phe17-Ala42). Radioactive fragments with molecular masses of 42, 36, 33 and 29 kDa were observed at 20, 60 and 180 min postingestion in the contents of the lower small intestine. Rats were given free access to milk enriched with lactoferrin at 482 micromol/L (40 mg/mL). The concentrations of lactoferrin fragments in the contents of the stomach, small intestine and lower small intestine as determined by SELDI affinity mass spectrometry were approximately 200, 20 and 1 micromol/L, respectively. These data indicate that functional fragments of LF such as fragments containing glycosaminoglycan-binding site(s), as well as large fragments with a mass >20 kDa, indeed survive proteolytic degradation in the small intestine of adult rats.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11481405     DOI: 10.1093/jn/131.8.2121

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  11 in total

Review 1.  Lactoferrin and necrotizing enterocolitis.

Authors:  Michael P Sherman
Journal:  Clin Perinatol       Date:  2013-01-17       Impact factor: 3.430

2.  Bovine lactoferrin induces interleukin-11 production in a hepatitis mouse model and human intestinal myofibroblasts.

Authors:  Tetsuya Kuhara; Koji Yamauchi; Keiji Iwatsuki
Journal:  Eur J Nutr       Date:  2011-06-19       Impact factor: 5.614

3.  Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells.

Authors:  Jamie S Mader; Daniel Smyth; Jean Marshall; David W Hoskin
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

4.  Lactoferrin reduces methotrexate-induced small intestinal damage, possibly through inhibition of GLP-2-mediated epithelial cell proliferation.

Authors:  Belinda van't Land; Noortje M A van Beek; Jeroen J M van den Berg; Laura M'Rabet
Journal:  Dig Dis Sci       Date:  2004-03       Impact factor: 3.199

5.  In vitro bioaccessibility and antioxidant properties of edible bird's nest following simulated human gastro-intestinal digestion.

Authors:  Zhang Yida; Mustapha Umar Imam; Maznah Ismail
Journal:  BMC Complement Altern Med       Date:  2014-12-05       Impact factor: 3.659

Review 6.  Novel approaches to improve the intrinsic microbiological safety of powdered infant milk formula.

Authors:  Robert M Kent; Gerald F Fitzgerald; Colin Hill; Catherine Stanton; R Paul Ross
Journal:  Nutrients       Date:  2015-02-12       Impact factor: 5.717

7.  Local application of lactoferrin promotes bone regeneration in a rat critical-sized calvarial defect model as demonstrated by micro-CT and histological analysis.

Authors:  Ryan Gao; Maureen Watson; Karen E Callon; Donna Tuari; Michael Dray; Dorit Naot; Satya Amirapu; Jacob T Munro; Jillian Cornish; David S Musson
Journal:  J Tissue Eng Regen Med       Date:  2017-04-09       Impact factor: 3.963

8.  Prevention of nosocomial infections in critically ill patients with lactoferrin (PREVAIL study): study protocol for a randomized controlled trial.

Authors:  John Muscedere; David Maslove; John Gordon Boyd; Nicole O'Callaghan; Francois Lamontagne; Steven Reynolds; Martin Albert; Rick Hall; Danielle McGolrick; Xuran Jiang; Andrew G Day
Journal:  Trials       Date:  2016-09-29       Impact factor: 2.279

9.  Lactoferrin and lysozyme to reduce environmental enteric dysfunction and stunting in Malawian children: study protocol for a randomized controlled trial.

Authors:  William D Cheng; Karl J Wold; Nicole S Benzoni; Chrissie Thakwalakwa; Kenneth M Maleta; Mark J Manary; Indi Trehan
Journal:  Trials       Date:  2017-11-06       Impact factor: 2.279

10.  The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.

Authors:  Yanmei Hu; Xiangzhi Meng; Fushun Zhang; Yan Xiang; Jun Wang
Journal:  Emerg Microbes Infect       Date:  2021-12       Impact factor: 7.163

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.